| RCT (Randomized Control Trial) of TD139 vs Placebo in HV's (Human Volunteers) and IPF Patients (NCT02257177) | Galecto Biotech AB | 2014-09-01 |
| Effects of an Oxymizer® During Daytime in Patients With Pulmonary Fibrosis (IPF) (NCT02268981) | Schön Klinik Berchtesgadener Land | 2014-09-01 |
| Azithromycin in Idiopathic Pulmonary Fibrosis (NCT02173145) | Insel Gruppe AG, University Hospital Bern | 2014-08-19 |
| Evaluate Safety and Efficacy of Intravenous Autologous ADMSc for Treatment of Idiopathic Pulmonary Fibrosis (NCT02135380) | Kasiak Research Pvt. Ltd. | 2014-08-01 |
| Post Marketing Surveillance of PIRESPA® TAB 200mg (Pirfenidone) for Evaluating the Safety and Efficacy (NCT03761082) | IlDong Pharmaceutical Co Ltd | 2014-07-01 |
| Auto-titrating Oxygen in Chronic Respiratory Failure (NCT02248064) | Imperial College London | 2014-07-01 |
| Clinical Progression of Mild to Moderate Idiopathic Pulmonary Fibrosis (IPF) Under a Therapy With Esbriet® (Pirfenidone) (NCT02622477) | Hoffmann-La Roche | 2014-06-01 |
| Modelling of Quality Life, Clinical and Physiological Measures in Idiopathic Pulmonary Fibrosis (NCT02176707) | University of East Anglia | 2014-06-01 |
| Bardoxolone Methyl Evaluation in Patients With Pulmonary Hypertension (PH) - LARIAT (NCT02036970) | Biogen | 2014-05-31 |
| Pilot Trial Of Omeprazole in Idiopathic Pulmonary Fibrosis (IPF) (NCT02085018) | Newcastle-upon-Tyne Hospitals NHS Trust | 2014-03-28 |
| Nandrolone Decanoate in the Treatment of Telomeropathies (NCT02055456) | University of Sao Paulo | 2014-02-01 |
| A Validation and Dosimetry Study of GSK2634673F PET Ligand (NCT02052297) | GlaxoSmithKline | 2014-01-24 |
| D2212C00002 J-Phase II Study (NCT02036580) | AstraZeneca | 2014-01-01 |
| Inhalation Profiling of Idiopathic Pulmonary Fibrosis (IPF) Patients (NCT02058602) | GlaxoSmithKline | 2013-12-03 |
| Treatment of IPF With Laparoscopic Anti-Reflux Surgery (NCT01982968) | University of California, San Francisco | 2013-12-01 |
| Nintedanib Twice Daily vs Placebo in Patients Diagnosed With Idiopathic Pulmonary Fibrosis (IPF) (NCT01979952) | Boehringer Ingelheim | 2013-11-26 |
| Study to Test the Validity of the Treatment of Idiopathic Pulmonary Fibrosis With Cotrimoxazole (NCT01777737) | Fundación Pública Andaluza para la gestión de la Investigación en Sevilla | 2013-11-25 |
| A Study of Lebrikizumab in Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT01872689) | Hoffmann-La Roche | 2013-10-13 |
| Long Term Effects of an Inpatient Pulmonary Rehabilitation Program in Patients With Pulmonary Fibrosis (NCT01772667) | Schön Klinik Berchtesgadener Land | 2013-10-01 |
| A Study to Assess the Safety and Tolerability of N-Acetylcysteine When Administered With Pirfenidone to Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT02707640) | Hoffmann-La Roche | 2013-08-01 |
| Evaluate the Safety and Efficacy of FG-3019 (Pamrevlumab) in Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT01890265) | Kyntra Bio | 2013-07-30 |
| Prospective Validation of Cough, Dyspnea, and Quality of Life Questionnaires in Patients With IPF (NCT01874223) | Stanford University | 2013-06-01 |
| The Role of Rheumatological Evaluation in the Management of Patients With Interstitial Lung Disease (NCT01809574) | Meir Medical Center | 2013-05-01 |
| Observational Study to Evaluate Disease Course and Outcomes in Patients Treated With Esbriet (Pirfenidone) for Idiopathic Pulmonary Fibrosis (IPF) in Canada (NCT02552849) | Hoffmann-La Roche | 2013-04-25 |
| A Proof of Mechanism Study With GSK2126458 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01725139) | GlaxoSmithKline | 2013-03-08 |
| Study of Default Options in Advance Directives (NCT01817686) | Corporal Michael J. Crescenz VA Medical Center | 2013-03-01 |
| Study of Autologous Mesenchymal Stem Cells to Treat Idiopathic Pulmonary Fibrosis (NCT01919827) | Clinica Universidad de Navarra, Universidad de Navarra | 2013-03-01 |
| Safety and Efficacy of Allogeneic Mesenchymal Stem Cells in Patients With Rapidly Progressive Interstitial Lung Disease (NCT02594839) | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | 2013-02-01 |
| Study to Assess the Efficacy and Safety of Simtuzumab (GS-6624) in Adults With Idiopathic Pulmonary Fibrosis (IPF) (NCT01769196) | Gilead Sciences | 2013-01-31 |
| Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis (NCT01766817) | Bristol-Myers Squibb | 2013-01-31 |
| The Role of Gastric Content Microaspirations in the Pathogenesis of Idiopathic Pulmonary Fibrosis (NCT01714934) | Sheba Medical Center | 2013-01-01 |
| Does CBT Improve the Perception/Impact of Cough and Breathlessness in IPF Patients (NCT01738711) | Royal Victoria Infirmary | 2012-12-01 |
| Long-Term Safety Study of GS-6624 in Adults With Idiopathic Pulmonary Fibrosis (IPF) (NCT01759511) | Gilead Sciences | 2012-10-18 |
| A Phase 2, Randomized Dose-ranging Study to Evaluate the Efficacy of Tralokinumab in Adults With Idiopathic Pulmonary Fibrosis (NCT01629667) | MedImmune LLC | 2012-10-01 |
| Investigating Significant Health Trends in Idiopathic Pulmonary Fibrosis (NCT01695408) | Technische Universität Dresden | 2012-10-01 |
| A MultiCenter Study of Combined PEX, Rituximab, and Steroids in Acute Idiopathic Pulmonary Fibrosis Exacerbations (NCT01524068) | University of Pittsburgh | 2012-09-01 |
| Conducting Airways in Lung Fibrosis (VACFI) (NCT01777373) | Assistance Publique - Hôpitaux de Paris | 2012-08-01 |
| Extension Trial of the Long Term Safety of BIBF 1120 in Patients With Idiopathic Pulmonary Fibrosis (NCT01619085) | Boehringer Ingelheim | 2012-06-06 |
| IPF Drug Deposition Study (NCT01457261) | Royal Brompton & Harefield NHS Foundation Trust | 2012-04-01 |
| Evaluation of Long-Term Safety of Pirfenidone (Esbriet) in Participants With Idiopathic Pulmonary Fibrosis (IPF) (NCT02699879) | Hoffmann-La Roche | 2012-02-16 |
| Exercise Training at Ambulatory Pulmonary Rehabilitation in Idiopathic Pulmonary Fibrosis Patients (NCT01499745) | Rabin Medical Center | 2012-01-01 |
| To Evaluate the Effect of Different Doses of SAR156597 Given to Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01529853) | Sanofi | 2012-01-01 |
| Safety and Efficacy Study of Pirfenidone to Treat Idiopathic Pulmonary Fibrosis(IPF) (NCT01504334) | Beijing Kawin Technology Share-Holding Co., Ltd. | 2012-01-01 |
| Clinical Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (NCT02136992) | Shanghai Pulmonary Hospital, Shanghai, China | 2011-12-01 |
| Double-blind Placebo-controlled Pilot Study of Sirolimus in Idiopathic Pulmonary Fibrosis (IPF) (NCT01462006) | University of Virginia | 2011-10-01 |
| Acute Effect of Sildenafil on Exercise Tolerance and Functional Capacity in COPD, IPF and Post Pneumonectomy Patients (NCT01382368) | Rabin Medical Center | 2011-09-01 |
| Safety and Tolerability Study of Macitentan in Patients With Idiopathic Pulmonary Fibrosis (NCT01346930) | Actelion | 2011-07-31 |
| Study of Inhaled Carbon Monoxide to Treat Idiopathic Pulmonary Fibrosis (NCT01214187) | Brigham and Women's Hospital | 2011-07-01 |
| Efficacy and Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01366209) | Genentech, Inc. | 2011-06-01 |
| A Phase 1b Study of IV PRM151 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01254409) | Hoffmann-La Roche | 2011-03-29 |
| Safety, Tolerability, and Efficacy Study of Idiopathic Pulmonary Fibrosis (NCT01262001) | Kyntra Bio | 2011-03-01 |
| Study in Subjects With PAH and PH Secondary to IPF Using Inhaled GeNOsyl. (NCT01265888) | Geno LLC | 2011-03-01 |
| A Study to Characterize the Safety, PK and Biological Activity of CC-930 in Idiopathic Pulmonary Fibrosis (IPF) (NCT01203943) | Celgene | 2011-01-01 |
| A Study to Evaluate the Safety and Efficacy of GS-6624 (Formerly AB0024) in Patients With Idiopathic Pulmonary Fibrosis (NCT01362231) | Gilead Sciences | 2010-12-01 |
| Safety and Efficacy of QAX576 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT01266135) | Novartis Pharmaceuticals | 2010-12-01 |
| A Study to Evaluate the Potential Role of Mesenchymal Stem Cells in the Treatment of Idiopathic Pulmonary Fibrosis (NCT01385644) | The Prince Charles Hospital | 2010-10-01 |
| Rehabilitation of Idiopathic Pulmonary Fibrosis (IPF) Patients (NCT01118221) | US Department of Veterans Affairs | 2010-10-01 |
| Prospective Observation of Fibrosis in the Lung Clinical Endpoints Study (NCT01110694) | Royal Brompton & Harefield NHS Foundation Trust | 2010-09-01 |
| Trial Of IW001 in Patients With Idiopathic Pulmonary Fibrosis (NCT01199887) | ImmuneWorks | 2010-09-01 |
| Prospective Study of Fibrosis In the Lung Endpoints (PROFILE - Central England) (NCT01134822) | University of Nottingham | 2010-07-01 |
| Safety and PK Study of BIBF 1120 in Japanese Patients With IPF (NCT01136174) | Boehringer Ingelheim | 2010-05-01 |
| CPAP Therapy in Patients With Idiopathic Pulmonary Fibrosis and Sleep Apnea (NCT01637831) | University of Crete | 2010-03-01 |
| Beneficial Effects of Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis (NCT01107028) | National Jewish Health | 2010-02-01 |
| Microaspiration in Pulmonary Fibrosis (NCT01150591) | University of California, San Francisco | 2009-12-01 |
| Correlating Outcomes With Biochemical Markers to Estimate Time-progression in Idiopathic Pulmonary Fibrosis (IPF) (NCT01071707) | University of Michigan | 2009-12-01 |
| AntiCoagulant Effectiveness in Idiopathic Pulmonary Fibrosis (NCT00957242) | Duke University | 2009-10-01 |
| Targeting Vascular Reactivity in Idiopathic Pulmonary Fibrosis (NCT00981747) | Alicia Gerke | 2009-09-01 |
| ARTEMIS-PH - Study of Ambrisentan in Subjects With Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis (NCT00879229) | Gilead Sciences | 2009-07-01 |
| Macitentan Use in an Idiopathic Pulmonary Fibrosis Clinical Study (NCT00903331) | Actelion | 2009-05-01 |
| 68Ga-DOTA-NOC PET/CT in Patients With Idiopathic Pulmonary Fibrosis (NCT01321996) | IRCCS Azienda Ospedaliero-Universitaria di Bologna | 2009-02-01 |
| Mechanisms of Familial Pulmonary Fibrosis (NCT03437486) | Vanderbilt University Medical Center | 2009-01-01 |
| Idiopathic Pulmonary Fibrosis Registry for Future Studies (NCT00815711) | Ohio State University | 2008-12-01 |
| (ARTEMIS-IPF) Randomized, Placebo-Controlled Study to Evaluate Safety and Effectiveness of Ambrisentan in IPF (NCT00768300) | Gilead Sciences | 2008-12-01 |
| Open-Label Study of the Long Term Safety of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT00662038) | Genentech, Inc. | 2008-08-01 |
| Role of Genetics in Idiopathic Pulmonary Fibrosis (IPF) (NCT01088217) | National Jewish Health | 2008-07-01 |
| Treprostinil Therapy For Patients With Interstitial Lung Disease And Severe Pulmonary Arterial Hypertension (NCT00705133) | Rajan Saggar | 2008-07-01 |
| Effects of Inhaled Treprostinil Sodium for the Treatment of Pulmonary Hypertension Associated With Idiopathic Pulmonary Fibrosis (NCT00703339) | Lung Biotechnology PBC | 2008-06-01 |
| Bosentan in Pulmonary Hypertension in Interstitial Lung Disease Treatment Study (NCT00637065) | Royal Brompton & Harefield NHS Foundation Trust | 2008-04-01 |
| Pulmonary Rehabilitation for Idiopathic Pulmonary Fibrosis (NCT00692796) | National Jewish Health | 2008-04-01 |
| Open Label Extension Study in Patients With Idiopathic Pulmonary Fibrosis Who Completed Protocol AC-052-321/ BUILD 3 / NCT00391443 (NCT00631475) | Actelion | 2008-04-01 |
| Treatment of Chronic Cough in Idiopathic Pulmonary Fibrosis With Thalidomide (NCT00600028) | Johns Hopkins University | 2007-12-01 |
| Pulmonary Arterial Hypertension Secondary to Idiopathic Pulmonary Fibrosis and Treatment With Bosentan (NCT00625469) | Rajan Saggar | 2007-10-01 |
| Pennsylvania Idiopathic Pulmonary Fibrosis Research Registry (NCT00540475) | University of Pittsburgh | 2007-09-01 |
| SD, IL-13 Production Rate in IPF (NCT00532233) | Novartis Pharmaceuticals | 2007-09-01 |
| Pulmonary Hypertension Secondary to Idiopathic Pulmonary Fibrosis And Treatment With Sildenafil (NCT00625079) | University of California, Los Angeles | 2007-02-01 |
| BUILD 3: Bosentan Use in Interstitial Lung Disease (NCT00391443) | Actelion | 2007-02-01 |
| Treatment of Idiopathic Pulmonary Fibrosis With Long Acting Octreotide (NCT00463983) | Institut National de la Santé Et de la Recherche Médicale, France | 2006-10-01 |
| Three-Arm Study of the Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (NCT00287716) | Genentech, Inc. | 2006-07-14 |
| Race, Ethnicity, and Diffuse Parenchymal Lung Disease (NCT00453713) | Columbia University | 2006-07-01 |
| Safety and Efficacy of Pirfenidone in Patients With Idiopathic Pulmonary Fibrosis (NCT00287729) | Genentech, Inc. | 2006-04-01 |
| Genomic and Proteomic Analysis of Disease Progression in Idiopathic Pulmonary Fibrosis (IPF) (NCT00373841) | University of Pittsburgh | 2005-10-01 |
| The Occurence of Inflammation and Oxidative Stress in Lung Diseases (NCT00512967) | Maastricht University Medical Center | 2005-09-01 |
| A Study of the Natural Progression of Interstitial Lung Disease (ILD) (NCT00470327) | University of Chicago | 2005-09-01 |
| Study of GC1008 in Patients With Idiopathic Pulmonary Fibrosis (IPF) (NCT00125385) | Genzyme, a Sanofi Company | 2005-07-01 |
| Azathioprine and Prednisone in the Treatment of Idiopathic Pulmonary Fibrosis (NCT00518310) | Thorax National Institute | 2005-05-01 |
| EZ-2053 in the Prophylaxis of Acute Pulmonary Allograft Rejection (NCT00105183) | Neovii Biotech | 2005-01-01 |
| To Evaluate the Use of Radiomics to Classify Between Idiopathic Pulmonary Fibrosis and Interstitial Lung Disease (NCT04430491) | Maastricht University | 2005-01-01 |
| Evaluation of Patients With Idiopathic Pulmonary Fibrosis (IPF) Through an IPF Registry (NCT00212511) | NYU Langone Health | 2004-11-01 |
| The INSPIRE Trial: A Study of Interferon Gamma-1b for Idiopathic Pulmonary Fibrosis (IPF) (NCT00075998) | InterMune | 2003-12-01 |
| Safety Study of Oral Pirfenidone in Patients With Pulmonary Fibrosis/Idiopathic Pulmonary Fibrosis (NCT00080223) | Genentech, Inc. | 2003-08-31 |